Otelixizumab

Generic Name: Otelixizumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 881191-44-2

Unique Ingredient Identifier: I5HF2X04PB

Background: Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity. Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.

Indication: Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cytokine Release Syndrome Treatment Market 2034: Clinical

The Cytokine Release Syndrome market is expected to surge due to increasing disease prevalence and awareness, with multiple-stage pipeline products revolutionizing market dynamics. The market report covers epidemiology, emerging drugs, current treatment practices, and market size from 2020 to 2034 in the United States, EU5, and Japan. Key companies and therapies include Swedish Orphan Biovitrum, Incyte, Kite (Gilead), Jazz Pharmaceuticals, and therapies like KINERET (anakinra) and Itacitinib. Market drivers include increasing incidence and R&D activities, while barriers include lack of awareness and misdiagnosis.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy